Cancer Treatment Reviews
Volume 31, Issue 8 , Pages 644-647, December 2005

Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma☆☆☆☆☆☆

Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland

published online 15 November 2005.

Abstracted from: Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–23.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: Grant from F. Hoffman-LaRoche Ltd.

☆☆ For correspondence: Robert Marcus, Department of Haematology, Addenbrookes Hospital, Cambridge CB2 2QQ, United Kingdom. Email: robert.marcus@addenbrookes.nhs.uk.

☆☆☆ Abstract provided by Bazian Ltd, London.

PII: S0305-7372(05)00195-7

doi:10.1016/j.ctrv.2005.09.010

Cancer Treatment Reviews
Volume 31, Issue 8 , Pages 644-647, December 2005

Article Tools